mymd is a clinical stage biotech pharmaceutical company committed to extending healthy lifespan by focusing on developing two therapeutic platforms. mymd-1 is a drug platform based on a clinical stage small molecule that regulates the immunometabolic system to control tumor necrosis factor alpha (tnf-α) and other pro-inflammatory cytokines. mymd-1 is being developed to treat autoimmune diseases, including those currently treated with non-selective tnf-α blocking drugs, and aging and longevity. supera-cbd is a drug platform based on a novel (patent pending) synthetic derivative of cannabidiol (cbd) that targets numerous key receptors including cb2 and opioid receptors and inhibits monoamine oxidase. supera-cbd is being developed to address the rapidly growing cbd market that includes fda approved drugs and cbd products not currently regulated as a drug.
Company profile
Ticker
MYMD
Exchange
Website
CEO
Howard Yeaton
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Akers Biosciences Inc, Akers Biosciences, Inc.
SEC CIK
Corporate docs
Subsidiaries
Akers Acquisition Sub, Inc. • Bout Time Marketing Corporation • XYZ Merger Sub Inc. ...
MYMD stock data
Latest filings (excl ownership)
8-K
Departure of Directors or Certain Officers
18 Apr 24
8-K
Entry into a Material Definitive Agreement
8 Apr 24
10-K
2023 FY
Annual report
1 Apr 24
8-K/A
Amendments to Articles of Incorporation or Bylaws
26 Mar 24
8-K
Entry into a Material Definitive Agreement
7 Mar 24
8-K
Regulation FD Disclosure
5 Mar 24
8-K
MyMD Pharmaceuticals Announces Reverse Stock Split to Maintain Nasdaq Listing
13 Feb 24
8-K
Regulation FD Disclosure
6 Dec 23
10-Q
2023 Q3
Quarterly report
14 Nov 23
8-K
MyMD Announces Preclinical Study Results Showing Novel Cannabidiol Analog, Supera-CBD™, Reduced
19 Oct 23
Latest ownership filings
SC 13G
Global X Management CO LLC
14 Feb 24
SC 13G/A
Iroquois Capital Management, LLC
14 Feb 24
4
Paul Rivard
24 Aug 23
4
Paul Rivard
18 Aug 23
4
Christopher C Chapman JR
9 Jun 23
4
Adam Kaplin
9 Jun 23
4
Jude Uzonwanne
9 Jun 23
4
Christopher C Schreiber
9 Jun 23
4
Joshua Silverman
9 Jun 23
4
CRAIG EAGLE
9 Jun 23
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 298.32 k | 298.32 k | 298.32 k | 298.32 k | 298.32 k | 298.32 k |
Cash burn (monthly) | (no burn) | 967.33 | (no burn) | 678.08 k | 1.05 mm | 1.11 mm |
Cash used (since last report) | n/a | 6.66 k | n/a | 4.67 mm | 7.24 mm | 7.63 mm |
Cash remaining | n/a | 291.66 k | n/a | -4.37 mm | -6.94 mm | -7.33 mm |
Runway (months of cash) | n/a | 301.5 | n/a | -6.4 | -6.6 | -6.6 |
Institutional ownership, Q3 2023
13F holders | Current |
---|---|
Total holders | 51 |
Opened positions | 12 |
Closed positions | 9 |
Increased positions | 11 |
Reduced positions | 11 |
13F shares | Current |
---|---|
Total value | 2.51 bn |
Total shares | 8.38 mm |
Total puts | 185.40 k |
Total calls | 44.60 k |
Total put/call ratio | 4.2 |
Largest owners | Shares | Value |
---|---|---|
Caroline C Williams | 3.75 mm | $9.26 mm |
Vanguard | 1.46 mm | $863.31 mm |
Mirae Asset Global Investments | 940.60 k | $556.84 mm |
Intracoastal Capital | 364.96 k | $2.21 mm |
Geode Capital Management | 291.23 k | $172.44 mm |
BLK Blackrock | 207.16 k | $122.64 mm |
Praetorian Wealth Management | 200.00 k | $118.40 mm |
Cambria Investment Management | 171.57 k | $101.57 mm |
Susquehanna International | 135.61 k | $80.28 mm |
STT State Street | 120.25 k | $71.19 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
24 Aug 23 | Paul Rivard | Common stock | Buy | Acquire P | No | No | 1.11 | 150,000 | 166.50 k | 400,000 |
17 Aug 23 | Paul Rivard | Common stock | Buy | Acquire P | No | No | 1.1232 | 25,000 | 28.08 k | 250,000 |
7 Jun 23 | Christopher C Schreiber | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 1.66 | 150,000 | 249.00 k | 150,000 |
7 Jun 23 | White Billy Joe | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 1.66 | 150,000 | 249.00 k | 150,000 |
7 Jun 23 | Christopher C Chapman JR | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 1.66 | 300,000 | 498.00 k | 300,000 |
News
Why Tilray Brands Shares Are Trading Lower By Around 22%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
9 Apr 24
MyMD Pharmaceuticals Filing From Late Monday Shows Co. Entered Omnibus Waiver And Amendment Agreement With Required Holders Under Previously Announced Securities Purchase Agreement
9 Apr 24
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
9 Apr 24
Why Biophytis Shares Are Trading Higher By Around 55%; Here Are 20 Stocks Moving Premarket
9 Apr 24
MyMD Pharmaceuticals Regains Compliance With Nasdaq Minimum Bid Price Requirement For Continued Listing
5 Mar 24
Press releases
Ladenburg Thalmann, Esteemed Wall Street Long-Standing Stalwart Since 1876, Advocates 'Buy' for Intelligent Bio, Precision Bio, and More: VTAK, INBS, LASE, MYMD, RVSN
9 Apr 24
MyMD Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement for Continued Listing
5 Mar 24
MyMD Pharmaceuticals Announces Reverse Stock Split to Maintain Nasdaq Listing
13 Feb 24